Mimedx (MDXG) Long-Term Investments (2014 - 2015)
Mimedx (MDXG) posted Long-Term Investments of $2.5 million for Q1 2015, down 23.08% sequentially from $3.2 million in Q4 2014.
Mimedx (MDXG) Long-Term Investments (2014 - 2015) Analysis & Trends
Mimedx has reported Long-Term Investments for 2 years, with the latest figure at $2.5 million in Q1 2015.
- Quarterly Long-Term Investments changed N/A year-over-year to $2.5 million in Q1 2015, while the trailing twelve-month figure through Mar 2015 was $2.5 million (changed N/A YoY) and the FY2014 annual result came in at $3.2 million, changed N/A from the prior year.
- Long-Term Investments eased to $2.5 million in Q1 2015 per MDXG's latest filing, from $3.2 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $3.2 million in Q4 2014 and troughed at $2.5 million in Q1 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2015 | 2.50 Mn |
| Dec 31, 2014 | 3.25 Mn |